Transvaginal Mesh Claims in Ireland: Medical Negligence and Product Liability Routes (2026 Guide)

Use this guide

What's New (2026): Department of Health received the National Vaginal Mesh Implant Oversight Group report in early 2025. Review remains pending. EU 2024/2853 transposes 9 December 2026.

Eligibility: Mesh implanted in Ireland or via TAS, complications confirmed mesh-related, within limitation. Section below covers the date-of-knowledge test.

Self-Audit: Implant date, current symptoms, prior consultation history, removal status, device manufacturer if known. Bring all five to the first consultation.

Before You Start: Request your medical records and preserve any explanted device retained by pathology.

Use-Cases: woman with chronic pelvic pain post-implant • partner researching for a family member • TAS-routed claimant • woman whose surgeon dismissed pain as non-mesh.

Contents

Quick answers

Time limit (medical negligence): Two years from your date of knowledge under the Statute of Limitations (Amendment) Act 1991, s.2.

Time limit (product liability): Three years from date of knowledge plus a strict ten-year longstop under the Liability for Defective Products Act 1991.

IRB applies? No. Section 3(d) of the PIAB Act 2003 exempts medical negligence. Product liability also bypasses the Injuries Resolution Board.

Redress scheme? No. The Government has not adopted one. Compensation is recovered through the courts.

In short: Most viable Irish mesh claims run two causes of action together. The medical negligence route runs against the surgeon or HSE on a two-year date-of-knowledge clock. The product liability route runs against the manufacturer on a three-year clock plus a ten-year longstop from when the device was placed on the market. Compensation follows the Personal Injuries Guidelines (2021), with multiple-injury uplift typical for mesh sequelae.

Comparing the three Irish legal routes for a mesh claim

This table summarises the Three-Route Mesh Claim Framework applied to Irish mesh injuries. Each row sets out one route. Where a case is strong on more than one row, the routes are run together.

Feature	Medical negligence	Product liability	Lack of informed consent
Defendant	Surgeon, treating consultant, or HSE through Clinical Indemnity Scheme	Manufacturer (e.g. Ethicon, Boston Scientific, Astora/Endo, Coloplast) or EU importer	Surgeon or hospital obtaining consent
Statutory framework	Common law negligence as restated in Dunne v National Maternity Hospital [1989] IR 91 and reaffirmed in Morrissey v HSE [2020] IESC 6	Liability for Defective Products Act 1991. After 9 December 2026, products placed on market thereafter governed by Directive (EU) 2024/2853	Patient-centred consent test in Fitzpatrick v White [2007] IESC 51
Time limit	Two years from date of knowledge under Statute of Limitations (Amendment) Act 1991, s.2	Three years from date of knowledge with strict 10-year longstop from placement on market	Two years from date of knowledge (same as medical negligence)
Burden of proof	Plaintiff must prove negligent breach of duty plus causation	Strict liability. Plaintiff proves defect plus causation, no negligence required	Plaintiff proves material risk not disclosed and causation through informed-choice test
IRB exemption	Yes. Exempt from Injuries Resolution Board under PIAB Act 2003, s.3(d)	Yes. Product liability claims also bypass IRB	Yes. Treated as medical negligence for IRB purposes
Strongest where	Surgical technique error, inappropriate case selection, post-op symptoms dismissed	Defective device placed on market, manufacturer disclosure failures, design or marketing defects	Material risks of mesh erosion, dyspareunia, irreversibility were not explained
Common defences	Acted in line with reasonable practice (Dunne test). Absence of breach	Development risk defence (1991 Act, s.6(e)) and regulatory compliance defence (s.6(d))	Risk was disclosed in writing. Would have proceeded anyway

Most plaintiffs combine routes. The medical negligence and consent claims are typically run together against the surgeon or HSE. The product liability claim runs in parallel against the manufacturer or its EU importer. See our detailed walkthrough of the three routes in detail below.

Why mesh claims in Ireland are different

Disambiguation: this guide covers transvaginal mesh, sometimes called vaginal mesh or pelvic mesh, used for stress urinary incontinence (SUI) and pelvic organ prolapse (POP). It does NOT cover hernia mesh, which is a different device class with different complications and a different Irish litigation profile.

The Irish picture is not the American picture, although you will find a great deal of US settlement coverage online. Ireland paused vaginal mesh procedures in July 2018 following the Chief Medical Officer's report on the use of uro-gynaecological mesh in surgical procedures. The procedure remains paused. Mesh implant surgery is not currently available in Ireland.

The advocacy group Mesh Survivors Ireland documented over 600 women affected by mesh complications. A separate group, Mesh Ireland, also represents affected women and addressed the Oireachtas Joint Committee on Health alongside Mesh Survivors Ireland in June 2022. Despite that combined advocacy, the Republic of Ireland has not adopted a financial redress scheme. While the UK Hughes Report (February 2024) recommended a two-stage redress scheme for women injured by pelvic mesh and sodium valproate, no equivalent has been introduced in Ireland. That has a practical consequence: if you were injured by a mesh implant in Ireland, court litigation is your only realistic path to compensation. Source: Oireachtas Joint Committee on Health hearing, 29 June 2022. The Journal (July 2023) reported Mesh Survivors Ireland membership at "around 600 women".

Ireland also has no national pelvic mesh registry. The UK established a Pelvic Floor Mesh Registry on the recommendation of the Cumberlege Review. The Republic has not. The absence is itself a litigation point because the State has no systematic outcomes data for the cohort of women implanted with mesh between the late 1990s and the 2018 pause. This makes individual medical records and direct patient reports to the Health Products Regulatory Authority more important, NOT less.

The mesh story in Ireland sits within a broader pattern of women's-health failings the State has had to confront. The Supreme Court decision in Morrissey v HSE [2020] IESC 6 arose from the CervicalCheck controversy. The duty to disclose information to a patient about her own condition, reaffirmed there, applies directly in mesh cases. Where a clinician knew (or had reason to suspect) that mesh was the source of a patient's pain and did not say so, the disclosure-duty argument is the same one the Supreme Court applied in Morrissey.

The Irish litigation posture is also different from the UK. The Supreme Court decision in Fitzpatrick v White [2007] IESC 51 established the patient-centred consent standard here, not the UK Montgomery v Lanarkshire principle. The Liability for Defective Products Act 1991 still governs strict product liability for any device placed on the market before 9 December 2026. The State Claims Agency manages mesh-related product liability claims arising in HSE hospitals. None of this is transferable from English or Northern Irish guides.

The other Irish-specific issue is data. The 2018 CMO report found that clinicians in Ireland were under-reporting mesh-related adverse events to both the Health Products Regulatory Authority and the National Incident Management System. As Marian Fogarty has set out for Irish Legal News, that under-reporting means the silence in regulator databases is not evidence the device was safe. It is a gap in the record. We will return to why that matters for evidence.

Three legal routes: medical negligence, product liability, lack of consent

Most Irish mesh claims that we see have at least two viable causes of action and often three. Each operates under different rules. The table sets out the core differences. The detail follows below.

Three-Route Mesh Claim Framework: comparing Irish causes of action for a transvaginal mesh injury

Route	Limitation	Defendant	What you must prove	IRB applies?
Medical negligence	Two years from date of knowledge	Surgeon, HSE, or private hospital	Treatment fell below standard expected of a competent practitioner (Dunne / Morrissey)	No (PIAB Act 2003, s.3(d))
Product liability	Three years from date of knowledge, ten-year longstop	Manufacturer (importer or distributor where applicable)	Product was defective and the defect caused the damage (strict liability)	No
Lack of informed consent	Two years from date of knowledge	Surgeon (or hospital under vicarious liability)	A material risk was not disclosed and you would not have consented if it had been (Fitzpatrick v White)	No (consent claims sit within medical negligence)

Medical negligence: the Dunne and Morrissey standard

The Irish test for medical negligence comes from Dunne v National Maternity Hospital [1989] IR 91, reaffirmed by the Supreme Court in Morrissey v HSE [2020] IESC 6. The question is whether no reasonable practitioner of equal status would have acted in the same way. For mesh, the negligence question often centres on case selection (was mesh appropriate for this patient at all), surgical technique (was the device placed correctly), and post-operative monitoring (was the patient's pain investigated or dismissed). A claim succeeds where independent expert evidence confirms a breach of duty, causation of injury, and quantifiable damage. See our guide on proving medical negligence.

This route catches a wide range of failures. We see informed consent issues most often, but case selection is also common where mesh was offered as a first-line option when conservative treatment had not been exhausted. Where the negligence is against an HSE-treated patient, the State Claims Agency manages the defence and any settlement. Where the surgery was private, the consultant's professional indemnity insurer is the paying party.

Product liability: the Liability for Defective Products Act 1991

According to the Liability for Defective Products Act 1991 on the Irish Statute Book, the 1991 Act imposes strict liability on the producer of a defective product. The plaintiff does not need to prove negligence by the manufacturer. She must prove that the device was defective and that the defect caused the damage. Manufacturers, importers into the EU, and certain distributors all fall within the chain of liability. For Irish mesh claims this typically means Ethicon (a Johnson & Johnson subsidiary), Boston Scientific, C.R. Bard, American Medical Systems / Astora (now under Endo, Inc. following 2024 emergence from Chapter 11), or Coloplast.

The Act has two limitation rules that work in tandem and frequently catch claimants out. Proceedings must be brought within three years of the date of knowledge of the defect, the damage, and the producer. Separately, there is a strict ten-year longstop running from the date the specific product was placed on the market. After ten years, the cause of action is extinguished even if the claimant has not yet discovered the injury. For mesh implanted before 2014, the longstop is now a real barrier. We address the practical consequences in the time limits section.

The 1991 Act will be replaced by Directive (EU) 2024/2853 for products placed on the market on or after 9 December 2026. The new regime extends the longstop to twenty-five years for latent personal injuries, recognises medically diagnosed psychological harm as compensable in its own right, and lowers the burden of proof in technically complex cases. The 1991 Act will continue to govern mesh placed on the market before that date, which covers virtually every device implanted in Ireland to date. We come back to the new regime below.

The Patient Information Leaflet and Instructions for Use

The manufacturer's Instructions for Use (IFU) and any Patient Information Leaflet issued with the device are central evidence in a product liability claim. If a complication you suffered was NOT listed as a risk in the IFU at the time of your implant, the device is potentially defective by failure-to-warn. If the complication WAS listed but the surgeon did not relay it to you in pre-operative consent, the manufacturer will plead the learned intermediary doctrine and your primary route is the consent claim. We obtain the IFU current at the time of your implant from the producer's regulatory file as part of disclosure.

Lack of informed consent: Fitzpatrick v White

Irish consent law has a patient-centred test that is particularly important in mesh cases. Fitzpatrick v White [2007] IESC 51 requires a surgeon to disclose any material risk that a reasonable patient in the patient's position would want to know. Geoghegan v Harris [2000] 3 IR 536 had earlier established the same principle for elective procedures. The risks of mesh erosion, chronic pelvic pain, dyspareunia, organ perforation, and the difficulty (or impossibility) of complete removal are all material risks under this test. If they were not explained, and you would not have consented if they had been, you may have a consent-based claim even if the surgery itself was performed competently. See our detailed page on lack of informed consent claims.

The Medical Council's Guide to Professional Conduct and Ethics (9th edition, 2024) sets the regulatory standard alongside the case law. It requires consent to be obtained in time for the patient to consider the information, free from pressure, and with an opportunity to ask questions. Rushed consent on the day of surgery does not meet the standard. Where a Notifiable Incident occurs, the Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023, which commenced on 26 September 2024, imposes a statutory duty of mandatory open disclosure on the health services provider. Failure to disclose a notifiable incident without reasonable explanation is a Class A offence under section 77 of the Act, and the breach itself can support the underlying negligence claim.

Why most mesh cases run all three routes

The three routes carry different limitation clocks and different evidentiary burdens. Running them together protects the claim against time-bar arguments and exploits weaknesses in each defence. A surgeon who can defend the technical performance may still face a consent claim. A manufacturer protected by the longstop on one device line may be exposed on another. We assess all three at the outset rather than picking one and discovering a gap later.

Two cases that shape mesh claims

Fitzpatrick v White [2007] IESC 51 (Supreme Court of Ireland, Kearns J, 15 November 2007)
Holding: A doctor must disclose any material risk that a reasonable patient in the patient's position would want to know. Late or rushed consent is not valid for elective procedures.
Why it matters: Consent claims are often the strongest mesh claim because risks of erosion, dyspareunia, and irreversibility were rarely fully disclosed.
Source: BAILII judgment

Morrissey v HSE [2020] IESC 6 (Supreme Court of Ireland, Clarke CJ, 19 March 2020)
Holding: The Dunne v National Maternity Hospital [1989] IR 91 test remains the standard for clinical negligence in Ireland. The question is whether no reasonable practitioner of equal status would have acted in the same way. The decision also imposed a wider duty to disclose information to a patient about her own condition.
Why it matters: Sets the standard against which a mesh surgeon's case selection, technique, and post-operative response are judged.
Source: BAILII judgment

Time limits: the date-of-knowledge problem

For mesh claims in Ireland, the medical negligence time limit is two years from your date of knowledge. The product liability limit is three years from your date of knowledge with a ten-year longstop from when the device was placed on the market. The clock is rarely the simple count from the date of surgery that competitors describe.

When the clock starts running

Date of knowledge is a statutory test. Per section 2 of the Statute of Limitations (Amendment) Act 1991 as published on the Irish Statute Book, the clock starts when the claimant first knew (or reasonably should have known) that she was injured, that the injury was significant, and that the injury was caused by the act or omission alleged to be negligent. For mesh, that test rarely satisfies on the day of surgery. Symptoms can emerge months or years later. Many women only discover that mesh is the cause when a second consultant identifies erosion that the first surgeon dismissed. In our experience that is the most common pattern in mesh enquiries: a long gap between the implant and the moment a clinician confirms what is wrong. The clock starts at confirmation, not at the original surgery date.

The ten-year product liability longstop

The ten-year longstop under the 1991 Act runs from the date the specific device was placed on the market by the producer. It is NOT a flexible test. After ten years, the right of action against the manufacturer is extinguished even if the woman has not yet discovered her injury. Mesh devices implanted before 2014 are now beyond that window for product liability purposes. The medical negligence and consent routes against the surgeon or hospital are not subject to the longstop, so older implants are not necessarily out of time, but the manufacturer route may be closed. Unlike in England and Wales, where the Limitation Act 1980 sets different rules, Ireland's ten-year longstop under the 1991 Act is statutory and cannot be extended by judicial discretion. This is one of the first issues we examine when assessing a claim.

The Date-of-Knowledge Reset: Section 71 of the Statute of Limitations 1957

Where a defendant has deliberately concealed facts relevant to the cause of action, time does not run while the concealment continues. According to the Irish Statute Book, Section 71 of the Statute of Limitations 1957 provides this exception. In the mesh context it can be relevant where a surgeon repeatedly attributed pain to non-mesh causes, knowing or having reason to suspect that the mesh was the source. The Mesh Survivors Ireland record contains many accounts of women being told for years that their pain was psychological or unrelated to the implant. Where that pattern can be evidenced, the limitation argument is materially different. We treat this as a Date-of-Knowledge Reset for cases where the original clinical position has been overtaken by later confirmation.

Date-of-Knowledge Reset Calculator

Enter your dates to see how the limitation clocks stand on your facts. Outputs are qualitative only.

Date your mesh was implanted: Date a clinician first confirmed the mesh as the cause: A previous clinician dismissed the mesh as the cause before this confirmation Calculate clock status

Causation: the but-for test and material contribution

Irish causation law starts from the "but for" test confirmed as the primary standard by the Supreme Court in Quinn v Mid-Western Health Board [2005] IESC 19 (Kearns J, 8 April 2005) and reaffirmed in Morrissey v HSE. The plaintiff must show that, but for the defendant's negligence or the product's defect, the injury would not have occurred. For mesh, this test is straightforward where the only causative factor in dispute is the device. Where pre-existing pelvic floor dysfunction, prior surgery, or other concurrent conditions are also in play, practitioners increasingly invoke the material contribution framework derived from the English authority Bonnington Castings Ltd v Wardlaw [1956] AC 613. Irish courts have not formally adopted material contribution as a freestanding standalone test, however. In Quinn itself, the Supreme Court rejected the adoption of broader alternative causation tests such as Fairchild, while keeping the door open in exceptional circumstances. The framework remains analytically relevant to many real mesh cases where the plaintiff already had urinary incontinence or prolapse before the implant. The Law Society Gazette analysis "Untangling the Threads" (November 2024) sets out the current Irish position in detail.

This leads to the question of which defendant actually pays.

How defendants will fight your claim

Knowing what HSE, the surgeon, and the manufacturer will argue is half the work of a mesh claim. The defences below are the ones we see at the start of every contested mesh proceeding in Ireland. None is fatal, but each has to be answered with evidence.

The development risk defence (1991 Act, s.6(e))

Manufacturers' first defence to a product liability claim is usually section 6(e) of the Liability for Defective Products Act 1991. This is the statutory "state of the art" or "development risk" defence. The producer escapes liability if "the state of scientific and technical knowledge at the time when [it] put the product into circulation was not such as to enable the existence of the defect to be discovered." For mesh, manufacturers have argued that complications such as long-term erosion or chronic pain were not foreseeable when the device was marketed in the late 1990s and early 2000s. Plaintiffs counter the defence with internal manufacturer documents, FDA correspondence (where disclosed in US litigation), peer-reviewed literature contemporaneous with marketing, and pharmacovigilance data showing the risk was knowable. The defence is not absolute and Irish courts have taken a relatively narrow view of what counts as "scientific and technical knowledge" available at the time.

The regulatory compliance defence (1991 Act, s.6(d))

Section 6(d) of the 1991 Act provides a defence where the defect resulted from compliance with a mandatory legal requirement. Manufacturers argue that the mesh was CE-marked, the production was compliant with the Medical Devices Directive, and the device met all applicable EU standards. This is NOT a complete answer. Compliance with regulations is relevant but does not preclude a defect finding under the 1991 Act. A regulator-compliant product can still fail the safety expectation test under section 5.

The learned intermediary doctrine

Manufacturers also argue that they discharged their duty to warn by giving information to the implanting surgeon (the "learned intermediary"), and that any failure to relay risks to the patient is the surgeon's responsibility, not theirs. This argument transforms a product-liability case into a consent-failure case against the surgeon. The plaintiff's strategy is to run both routes together. If the warning was adequate, the failure was the surgeon's. If it was not adequate, the manufacturer is on the hook for a defect-by-warning claim.

The Dunne defence and standard of care

For the medical negligence route, the surgeon's defence is built around the Dunne / Morrissey standard. The argument is that the practitioner acted as any reasonable practitioner of equal status would have acted in the same circumstances. For mesh, that often means citing the Royal College of Obstetricians and Gynaecologists or American Urogynecologic Society guidelines that were in force at the time. Plaintiffs answer this with independent expert evidence that the surgeon's specific case selection, technique, or post-operative response fell below the standard of a competent practitioner.

Time-bar arguments and how to answer them

Defendants will routinely plead the Statute of Limitations. The exchange usually runs as follows. The defendant says the implant was placed years ago, time has expired. The plaintiff replies that date of knowledge under section 2 of the 1991 Amendment Act runs from confirmation of the mesh as the cause of injury, NOT from the implant date. Where a previous clinician dismissed the connection, section 71 of the Statute of Limitations 1957 may apply. The product liability ten-year longstop is harder to answer and may exclude older devices from the manufacturer route.

Contributory negligence and pre-existing conditions

Defendants sometimes plead that the plaintiff's symptoms predate the mesh, or that obesity, smoking, or other lifestyle factors contributed to the failure. Under the Civil Liability Act 1961, contributory negligence reduces (it does NOT extinguish) the damages award. The plaintiff's answer is medical evidence on causation that distinguishes the mesh-caused injury from any pre-existing baseline.

Who actually pays: HSE, private hospital, manufacturer, or all three

The defendant in a mesh claim depends on where the implant was placed and which causes of action you are running. Identifying the right defendant early matters because each has different procedural rules, different insurers, and different willingness to settle.

HSE-implanted mesh: the State Claims Agency pathway

If your mesh was implanted in an HSE hospital, the defence is managed by the State Claims Agency under the Clinical Indemnity Scheme. In January 2022 the Government also routed product liability claims for mesh through the State Claims Agency in the HSE setting, which means the State picks up the manufacturer-side defence as well rather than leaving hospitals exposed to private-insurance gaps. This produces a centralised defence position. Settlements tend to follow a measured timeline with no admission of liability.

Privately implanted mesh: consultant indemnity

If your mesh was placed in a private hospital by a private consultant, the defence is run by the consultant's professional indemnity insurer (typically the Medical Protection Society or a similar mutual). The hospital may also be a defendant in its own right. The same medical negligence and consent tests apply. Costs and timelines are governed by the same Irish court rules.

Manufacturer claims: the 1991 Act and the Astora problem

A claim against the device manufacturer runs separately from the surgical claim. The defendant is the producer that placed the device on the EU market. For older devices this is often a US parent (Johnson & Johnson via Ethicon, or Endo via American Medical Systems and Astora), with Irish service typically effected on a European subsidiary. Astora Women's Health LLC filed for Chapter 11 protection in August 2022 as part of Endo International plc's wider bankruptcy proceedings in the United States. Endo emerged from Chapter 11 in 2024 with assets transferred to a successor entity, Endo, Inc. The UK Insolvency and Companies Court has recognised the Chapter 11 proceedings as a foreign main proceeding, which has stayed and complicated mesh claims against Astora across these islands. A claim that would otherwise be straightforward may need to be progressed through the US bankruptcy framework or against alternative economic operators in the supply chain. Unlike in the United States, where mesh claimants accessed multidistrict litigation pools and broad class action mechanisms, Irish claimants must pursue individual proceedings or use the Representative Actions Act 2023 framework, which is narrower in scope. The post-9 December 2026 regime under Directive (EU) 2024/2853 expands liability to importers and fulfilment service providers, which will help future claimants but does not retroactively assist those whose devices were placed on the market before that date.

Common mesh devices used in Ireland and their longstop position

The producer for each device determines who you serve. The longstop year tells you when the manufacturer route is extinguished under the 1991 Act for a typical implant placed in that period.

Manufacturers and approximate Irish longstop position for common transvaginal mesh devices. Specific dates depend on the actual placement date of your device.

Device family	Producer	Implant range (Ireland)	1991 Act longstop expires
Gynecare TVT, TVT-O, Prolift	Ethicon (Johnson & Johnson)	1998 to 2018 pause	2008 to 2028 (per device)
Obtryx, Solyx, Advantage Fit	Boston Scientific	2002 to 2018 pause	2012 to 2028 (per device)
Avaulta, Align	C.R. Bard (now BD)	2003 to 2016	2013 to 2026 (per device)
Monarc, Apogee, Perigee	American Medical Systems / Astora (now Endo)	2004 to 2018 pause	2014 to 2028 (per device)
Aris, Restorelle, Altis	Coloplast	2005 to 2018 pause	2015 to 2028 (per device)

The longstop runs ten years from the date the specific device was placed on the market, not from the implant date. If your operative note records the device, your solicitor can verify the actual longstop with the producer's regulatory file.

At this point, the natural question is what compensation you can expect. That depends on the Personal Injuries Guidelines and how multiple injuries combine.

How compensation is calculated

Mesh damages follow the same Irish framework as any other personal injury or medical negligence claim. General damages (pain and suffering) are assessed under the Personal Injuries Guidelines adopted in April 2021. Special damages (financial losses) are calculated separately on the basis of vouched losses. The headline figures from US multi-district litigation are not transferable to Irish awards.

Personal Injuries Guidelines: the reproductive system: female bracket

The Personal Injuries Guidelines (2021) remain the operative framework. The Guidelines include a chapter on reproductive system: female injuries which covers many of the typical mesh sequelae. The Judicial Council approved a 16.7% inflation increase on 31 January 2025 and submitted the draft amendments to the Minister for Justice on 4 February 2025, but the proposal was not brought before the Oireachtas for vote and did not come into force. The 2021 Guidelines and the existing €550,000 cap on general damages therefore continue to apply. See our note on the 2026 update to the Personal Injuries Guidelines for the procedural background.

The multiple-injury uplift mechanic

Mesh injuries rarely sit in a single Guidelines bracket. A typical case can involve mesh erosion, chronic pelvic pain, dyspareunia, recurrent urinary tract infection, and a diagnosed depressive or anxiety disorder secondary to chronic pain. Each of those sits in a different chapter of the Guidelines. The court does not simply add the brackets together. It identifies the most severe (the dominant injury) as a baseline, then applies a proportional uplift to reflect the lesser concurrent injuries. The uplift mechanic is well explained by Mason Hayes & Curran in their analysis of multiple-injury awards. Properly pleaded, the multiple-injury uplift can produce a materially higher general damages award than a single-bracket reading.

Special damages and future care

Beyond general damages, the claim covers special damages for vouched financial losses. For mesh cases this typically includes the cost of revision or removal surgery (often abroad, where Irish removal capacity is limited), travel and accommodation for that surgery, lost earnings during recovery, and ongoing pain management. Where the injury results in lasting disability, future care costs are quantified by an actuary on the basis of a medical prognosis. In catastrophic cases, periodic payment orders may be available as an alternative to a single lump sum.

Worked example: how the Guidelines apply to a typical mesh fact pattern

Consider a 52-year-old woman whose mesh was implanted in 2017, with chronic pelvic pain confirmed mesh-related in late 2024 after a second consultant's review. Removal surgery was undertaken in 2025. She has dyspareunia, recurrent urinary tract infection, and a diagnosed adjustment disorder secondary to chronic pain. The Guidelines categories engaged are: reproductive system: female (dominant injury), urinary tract chapter (recurrent infection), and psychiatric damage generally (adjustment disorder).

The court identifies the dominant injury at the moderate-to-severe end of the reproductive bracket and sets a baseline figure within that band. It then applies a multiple-injury uplift to reflect the concurrent injuries, sized proportionally so the total stays within the Guidelines framework rather than summing each bracket. The total general damages award is therefore higher than a single-bracket reading would suggest, but lower than a simple addition. Special damages add the cost of UK removal surgery, travel and accommodation for surgery, lost earnings during the recovery period, and the cost of ongoing pain management. The €550,000 cap on general damages is the ceiling for the most catastrophic injuries, NOT the typical mesh outcome. Specific figures depend entirely on the medical evidence in your own case. Mason Hayes & Curran's analysis sets out the uplift methodology in more detail.

The next step is the procedural reality: how a mesh claim actually moves through the Irish High Court.

↑ Back to top

How a mesh claim runs in Ireland

Medical negligence claims for mesh injury are exempt from the Injuries Resolution Board under section 3(d) of the PIAB Act 2003 and proceed directly to the High Court. Product liability claims under the 1991 Act also bypass the IRB and are issued directly. The five-stage path that follows applies to both routes.

1) Initial assessment. A solicitor reviews the implant date, symptom timeline, prior clinical interactions, and any consent documents. The objective is to identify which causes of action are viable and where the limitation clocks stand. This is where the longstop and date-of-knowledge analysis happens.

2) Records and expert opinion. Your medical records are requested from the original implanting hospital, any subsequent treating hospital, and the GP. An independent expert medical report is obtained from a urogynaecologist or a relevant consultant with experience in mesh complications. Irish courts treat the issuing of medical negligence proceedings without a supportive expert report as an abuse of process, so the report is required before proceedings are issued.

3) Proceedings. A personal injury summons is issued in the High Court. For multi-defendant cases (surgeon, HSE, manufacturer), each defendant is served separately. The plaintiff's legal team continues to gather expert evidence on causation and quantum during the pleadings phase.

4) Expert exchange and case management. Practice Direction HC131 and HC132, which took effect on 28 April 2025, require all expert reports to be exchanged before a trial date can be assigned and create a dedicated Clinical Negligence List with experienced judicial oversight. This has compressed the historical timetable. Cases that previously sat for years before substantive engagement now move through a managed schedule.

The Section 8 letter of claim: what belongs in it for mesh

The Civil Liability and Courts Act 2004, section 8 requires a plaintiff to write to the defendant stating the basis of the claim within two months of the cause of action accruing (or as soon thereafter as is practicable). For mesh, the letter should specify the device family and (where known) the catalogue number, the implant date, the implanting surgeon and hospital, the alleged failures (case selection, technique, consent, defect, warning), the causation chain from implant to current injury, the heads of loss pleaded, and the date on which the plaintiff says her date of knowledge crystallised. A generic "you are negligent" letter is not enough and exposes the plaintiff to costs consequences under section 8(2) of the 2004 Act.

Mediation under the Mediation Act 2017

The Mediation Act 2017 places solicitors under a statutory duty to advise clients on mediation as an alternative to litigation. For mesh claims, mediation has become a regular feature of the post-HC131 case management timetable. The State Claims Agency mediates a substantial proportion of HSE-defended cases. Mediation does not commit you to anything: anything said in mediation is privileged and inadmissible if the case proceeds to trial. The ordinary use is at a point where both sides have exchanged expert reports and have a clear view of the case, but before fixed trial costs accrue.

Costs, fees, and the Section 150 estimate

Sections 150 and 151 of the Legal Services Regulation Act 2015 require a solicitor to give a written cost estimate at the outset of every engagement. Mesh claims sit at the higher end of medical negligence cost ranges. Independent expert medical reports for mesh typically cost between €5,000 and €25,000 depending on the seniority of the expert and the complexity of the report. Senior counsel fees and consultative engineering experts (for the device itself) add to the total. Most mesh enquiries proceed on a fees-deferred or "no win no fee" basis. Costs in High Court personal injury and medical negligence proceedings ordinarily follow the event under section 169 of the Legal Services Regulation Act, meaning the losing party pays the winning party's costs as taxed.

HSE Mesh Complications Services: the medical pathway

The HSE established a national mesh complications service following the 2018 pause. Funding of €500,000 per hospital was approved in 2020, and the service has been fully operational since 1 September 2021. The service operates through two National Complex Pelvic Floor Centres at the National Maternity Hospital in Dublin and Cork University Maternity Hospital. Access is by referral from your GP or treating consultant. The service is structured as a three-tiered response: primary care, regional referral centres with experienced clinicians, and the two complex pelvic floor centres. As of the June 2022 Oireachtas Joint Committee on Health hearing, the Cork centre had seen 40 patients with no waiting list, and the Dublin centre had seen 69 patients with a waiting list of 16. The Institute of Obstetricians and Gynaecologists published the National Clinical Guideline on Diagnosis and Management of Mesh Complications in 2023, which sets out the clinical algorithm for triage and treatment and adopts the IUGA-ICS classification of complications. From a litigation perspective, attendance at one of the complex centres produces a comprehensive multidisciplinary clinical assessment that becomes important evidence in the medical negligence and product liability claim. HSE support services page.

What Holohan 2018 recommended and what the State has done

The Chief Medical Officer's report on the use of uro-gynaecological mesh, published in November 2018 by Dr Tony Holohan, made nineteen recommendations. The headline recommendations included a pause on mesh procedures, the establishment of a multidisciplinary mesh complications service, accessible information for women about mesh complications, referral pathways across the hospital groups, the inclusion of treatment abroad where necessary, and improvements to adverse event reporting. The HSE has implemented many of the recommendations, most prominently the two complex pelvic floor centres and the referral pathways. Other recommendations remain partially complete or contested by patient advocacy groups. The full implementation status is not in the public domain in fully audited form. For litigation purposes, the gap between recommendation and implementation is itself relevant: it shows the State on notice of risk that was not always operationally addressed.

5) Negotiation, mediation, or trial. Most Irish medical negligence and mesh product liability cases settle before trial. Mediation is increasingly used. Where settlement is not possible, the case is heard by a High Court judge sitting without a jury.

What evidence to preserve

Three categories of evidence matter for a mesh claim. The checklist below maps each artefact to the cause of action it supports.

Mesh evidence preservation checklist by cause of action

Evidence artefact	How to secure	Supports which route
The explanted device itself	Ask the removing hospital's pathology department in writing, before surgery if possible, to retain the device for engineering examination	Product liability (engineering proof of defect)
Operative note from original implant	Request your records from the implanting hospital under the data subject access request procedure	All three routes (identifies device + technique)
Notes of every consultation since the implant	Same records request to include GP, treating consultant, A&E attendances	Medical negligence (case selection, technique) + Date-of-Knowledge Reset (dismissal pattern)
Original consent form	Hospital records. If missing, this itself is a consent-claim issue	Lack of informed consent (Fitzpatrick)
Imaging (transvaginal ultrasound, MRI) confirming mesh erosion or position	Request reports and image files from radiology	Causation in all three routes
Direct HPRA adverse-event report submitted by you	File via the HPRA reporting portal	Product liability (independent record bypassing clinician under-reporting)
Receipts for removal surgery, travel, accommodation, lost earnings	Keep all originals and vouch every item	Special damages
Independent expert medical report	Instructed through your solicitor	Required to issue medical-negligence proceedings (Reidy v National Maternity Hospital)

The single most often missed item is the explanted device. Removal surgery routinely sends mesh to pathology for histology, but unless the patient or solicitor explicitly asks for retention, the device is destroyed after the histology report. Request retention in writing before any removal surgery if possible.

What this means for women on the Treatment Abroad Scheme

While the HSE pause on mesh procedures is in effect domestically, the State has continued to fund mesh-related procedures abroad through the Treatment Abroad Scheme (TAS). Some Irish women have been routed to UK or European centres for the same procedure that is paused at home, and complications then return to Ireland for management. The contradiction matters for two reasons. Where a TAS-funded procedure went wrong, the legal route depends on where the surgery occurred and whether the surgeon was an Irish practitioner working abroad. Where consent was obtained without disclosure of why mesh was paused at home, that is a strong informed-consent argument under Fitzpatrick v White. We assess these cases on the same three-route framework as domestic implants but with cross-border conflict-of-laws issues that need separate handling early.

Mesh removal abroad: realities and recoverable costs

For women whose existing mesh has caused complications, the practical question is often where to obtain removal surgery. Prof Declan Keane at the National Maternity Hospital in Dublin has stated that full mesh removal is extremely complex and that he personally has supported some patients to attend Dr Dionysios Veronikis in St. Louis, Missouri, for full excision. UK centres including the Bristol Pelvic Floor Service also accept Irish private patients. Within Ireland, partial excision is more commonly performed than full excision, which produces clinical and legal questions about residual mesh and subsequent symptoms. Where overseas removal is medically indicated and reasonable, the cost is recoverable as special damages in your claim, including travel and accommodation costs for the patient and a companion where reasonable. Keep all receipts and any medical referral letter that supports the necessity of the overseas procedure.

How EU Directive 2024/2853 affects future mesh implants

The Revised Product Liability Directive enters Irish law on 9 December 2026. It applies to products placed on the market on or after that date. For mesh, the practical effect is limited in the near term because the procedure remains paused. If and when it resumes, any new device will fall under the new regime. The new rules extend the long-stop limitation from ten years to twenty-five for latent personal injuries, recognise medically diagnosed psychological harm as compensable in its own right, and allow courts to presume a defect where the technical complexity of the device makes proof excessively difficult. The Liability for Defective Products Act 1991 continues to govern any device placed on the market before 9 December 2026, which covers all current Irish mesh claims. Ireland's transposition timetable is on track. The Department of Enterprise, Trade and Employment confirmed in 2025 that the deadline is expected to be met.

Decision tree: do I have a mesh claim?

Mesh claim eligibility checker

A 6-question preliminary assessment. Outputs are qualitative only and are not a substitute for legal advice.

1. When was your mesh implanted?

Implant date (approximate is fine):

Next

Common mistakes that sink mesh claims

• Assuming the implant date is the date of knowledge. The clock starts on confirmation, which is often years later.
• Pursuing only the manufacturer when the medical negligence and consent routes may be the stronger claim.
• Letting the explanted device be discarded after removal surgery. Pathology should retain it. Ask explicitly.
• Treating the IRB as the first step. Both medical negligence and product liability claims bypass the Injuries Resolution Board entirely.
• Relying on US settlement figures for compensation expectations. Irish damages follow the Personal Injuries Guidelines.
• Waiting because there is no urgency. The 1991 Act ten-year longstop runs whether or not anyone has confirmed the diagnosis.

Frequently asked questions

Is there a Government redress scheme for vaginal mesh in Ireland?

No. The Government has not adopted a redress scheme for women injured by vaginal mesh in the Republic of Ireland. The UK Hughes Report (February 2024) recommended one for the UK, but Northern Ireland and Britain have not yet implemented it either. In the Republic, compensation is recovered through litigation under medical negligence law and the Liability for Defective Products Act 1991.

• Mesh Survivors Ireland and others have campaigned for a scheme.
• The State has not committed to one.
• Litigation is the only realistic route to compensation.

Why it matters: If you are waiting for a scheme, the limitation clocks are still running.

Next step: Medical negligence overview • HSE pause page (2026)

How long do I have to claim if my mesh was implanted in 2010?

The medical negligence and consent routes against the surgeon or hospital depend on your date of knowledge, not the implant date. If a clinician only confirmed the mesh as the cause of your pain in the last two years, you may be in time. The product liability route against the manufacturer is governed by the ten-year longstop under the 1991 Act, which has likely now expired for a 2010 implant. The two questions are separate.

• Medical negligence: two years from date of knowledge.
• Product liability: three years from date of knowledge plus ten-year longstop.
• Section 71 concealment may extend the clock if a surgeon withheld a mesh diagnosis.

Why it matters: A claim that is barred against the manufacturer may still run against the surgeon.

Next step: Date of knowledge guide • Medical negligence time limits

My surgeon told me my pain wasn't mesh-related. Has my time run out?

Not necessarily. Date of knowledge is when you knew or reasonably should have known that the mesh was the cause. If a surgeon repeatedly attributed your pain to other causes and a different clinician later identified the mesh, the clock starts at that later confirmation. Section 71 of the Statute of Limitations 1957 also extends the limitation period where a defendant deliberately concealed relevant facts. Both points need a solicitor's review on the specific facts.

• The clock starts on confirmation, not original surgery.
• Concealment by a clinician may reset the clock further.
• This is the most common pattern in mesh enquiries we see.

Why it matters: Many women assume they are out of time when they are not.

Next step: Date of knowledge • Call 01 903 6408

Can I claim if my mesh was placed privately, not in HSE?

Yes. Private consultants in Ireland have the same duty of care as HSE consultants. The defence is run by the consultant's professional indemnity insurer rather than the State Claims Agency, but the legal tests are the same. The hospital may also be a defendant where institutional failings are alleged.

• Same Dunne and Fitzpatrick standards apply.
• Defendant identity changes, not the law.
• Hospital and consultant may both be on the proceedings.

Why it matters: Private treatment does not reduce your rights.

Next step: Eligibility guide • Surgical negligence claims

Do I have to go through the Injuries Resolution Board?

No. Section 3(d) of the PIAB Act 2003 exempts claims arising out of medical or surgical procedures from the Injuries Resolution Board (formerly PIAB). Product liability claims under the 1991 Act also bypass the IRB. Both go directly to the High Court.

• Medical negligence claims are exempt under PIAB Act 2003 s.3(d).
• Product liability claims also bypass the IRB.
• Mesh claims are issued directly in court.

Why it matters: Skipping the wrong gateway is a common procedural error.

Next step: Medical negligence overview • PIAB Act 2003, s.3(d)

How much could I get for a mesh claim?

Compensation depends on your specific injuries, recovery, and proven losses. General damages are assessed under the Personal Injuries Guidelines (2021), which are still in force after the failed 2025 update. The reproductive system: female chapter typically applies, with multiple-injury uplift where mesh has caused several distinct sequelae. Special damages cover removal surgery costs, lost earnings, and future care. We do not give fixed figures because every case differs and outcomes vary.

• Personal Injuries Guidelines (2021) set the framework.
• Multiple-injury uplift commonly applies.
• Special damages cover removal, travel, and lost earnings.

Why it matters: Realistic ranges depend on medical evidence, not headlines.

Next step: General damages guide • Special damages guide

What if the manufacturer is in liquidation, like Astora?

Astora Women's Health LLC filed Chapter 11 in August 2022. Endo International plc emerged from Chapter 11 in 2024 with assets transferred to a successor entity, Endo, Inc., though Astora-specific claims remain affected by the US bankruptcy framework. Irish claims may need to proceed through US bankruptcy proceedings or against alternative economic operators in the supply chain. The medical negligence and consent routes against the surgeon or hospital are unaffected by manufacturer insolvency.

• US bankruptcy proceedings may stay direct claims.
• Surgical and consent claims continue independently.
• Future EU 2024/2853 regime expands liability to importers and distributors.

Why it matters: Manufacturer liquidation does not end your claim.

Next step: Medical negligence routes • Call 01 903 6408

Can my partner claim too?

In limited circumstances, yes. Irish law recognises secondary victim claims where a close family member suffers nervous shock as a result of witnessing or learning of an injury to a primary victim. The threshold is high and the medical evidence requirements are strict. A partner whose own life has been materially affected (loss of consortium, loss of earnings to provide care) may also have separate heads of claim.

• Secondary victim claims have a high threshold.
• Care-related losses are recoverable as part of the primary claim.
• Each case turns on specific facts.

Why it matters: The household impact of mesh injury can be substantial.

Next step: Who can claim

Will the EU Directive 2024/2853 help my old mesh case?

No. The Revised Product Liability Directive applies only to products placed on the market on or after 9 December 2026. The Liability for Defective Products Act 1991 continues to govern every device implanted in Ireland to date, including the ten-year longstop. The new Directive matters for any future mesh procedures that may resume after the pause is lifted.

• 2024/2853 applies forward only.
• 1991 Act governs current Irish mesh claims.
• The longstop position does not change for existing devices.

Why it matters: Some online commentary suggests the Directive helps existing claimants. It does not.

Next step: Directive (EU) 2024/2853

How do I start a mesh claim?

Speak to a solicitor as early as possible. The first step is a confidential review of the implant date, your symptom timeline, and any consent documents. From there the priority is requesting your medical records and obtaining an independent expert report. Most enquiries proceed on a fees-deferred basis. We give written cost estimates at the outset under sections 150 and 151 of the Legal Services Regulation Act 2015.

• Initial assessment is confidential and free.
• Records request and expert report follow.
• No win no fee available for qualified cases.

Why it matters: Time pressure is real, but the early steps protect your position.

Next step: No win no fee guide • Call 01 903 6408

What if I had mesh placed in another country and the complications presented in Ireland?

The legal route depends on where the surgery occurred, who performed it, and the cause of action. A medical negligence claim against a foreign surgeon is governed by the law of the country where the procedure took place. A product liability claim against the manufacturer can be brought in Ireland under EU jurisdiction rules where the manufacturer is established in the EU and the damage occurred here. The analysis is complex and needs to be done at the outset.

• Surgical claim follows the place of treatment.
• Manufacturer claim can often be brought in Ireland.
• Conflict-of-laws issues need early review.

Why it matters: Many TAS-routed and cross-border procedures fall here.

Next step: Call 01 903 6408 for a cross-border review.

What if my surgeon has retired or died?

The claim is not extinguished. A medical negligence claim against an HSE consultant is defended by the State Claims Agency under the Clinical Indemnity Scheme regardless of the surgeon's current status. A claim against a retired private consultant is defended by his or her professional indemnity insurer (Medical Protection Society or similar). Where the surgeon is deceased, the proceedings are issued against the estate or, more commonly, against the hospital under vicarious liability.

• HSE cases continue against the State Claims Agency.
• Private cases continue against the indemnity insurer.
• Hospital may be defendant under vicarious liability.

Why it matters: Defendant identity changes, not the claim's viability.

Next step: Eligibility guide

Can mesh be partially or only fully removed?

Both. Partial excision removes the most problematic section of mesh. Full excision removes all mesh material. Full excision is technically demanding because mesh integrates with surrounding tissue, and not all surgeons offer it. Within Ireland, Prof Declan Keane at the National Maternity Hospital has stated full removal is "extremely complex" and that some patients have travelled to Dr Veronikis in the United States for full removal. The clinical decision affects both the cost recoverable as special damages and the remaining symptom profile.

• Partial excision more commonly available in Ireland.
• Full excision often abroad (US, UK).
• Choice has both clinical and litigation consequences.

Why it matters: Removal route affects damages and prognosis.

Next step: HSE support services

What does a mesh expert report cost?

Independent expert medical reports for mesh typically cost between €5,000 and €25,000 depending on the seniority of the expert, the volume of clinical records to review, and the complexity of the causation analysis. Engineering experts for the device itself add further cost. Most enquiries proceed on a fees-deferred basis with the cost of expert reports advanced by the firm and recovered from the defendant on settlement.

• Expert report costs reflect the depth of expertise required.
• Fees-deferred arrangements common.
• Recovered as part of legal costs on settlement.

Why it matters: Expert costs should not be a barrier to claim.

Next step: No win no fee guide

Will I have to give evidence in court?

Most Irish mesh medical negligence and product liability cases settle before trial. Where a case does proceed to trial, the plaintiff typically gives evidence about the implant decision, the consent discussion, the symptom timeline, and the impact on her life. The medical and engineering evidence is given by independent experts. Trial preparation includes detailed proofing with your solicitor and counsel. The Clinical Negligence List under HC132 provides a managed environment with experienced judicial oversight.

• Most cases settle before trial.
• If trial is required, plaintiff evidence is prepared in advance.
• Clinical Negligence List provides experienced judicial management.

Why it matters: Most plaintiffs are concerned about the prospect of giving evidence.

Next step: Expert reports guide

Can a male partner claim for loss of consortium?

Loss of consortium is no longer a separate cause of action in Ireland following the Family Law Act 1981, but the practical impact on the claimant's relationship and partner is recoverable as part of her general damages award. A partner who has incurred specific financial loss (lost earnings to provide care, paid services replacing the claimant's domestic contribution) may have separate heads of claim under the Civil Liability Act 1961. Secondary victim claims for nervous shock have a high threshold and are rare in mesh cases.

• Partner financial losses recoverable in primary claim.
• Loss of consortium subsumed into general damages.
• Independent secondary victim claims rare.

Why it matters: Households often bear costs beyond the patient.

Next step: Who can claim

What is the difference between mesh erosion, mesh exposure, and mesh extrusion?

The terms are used interchangeably in the public press but are clinically distinct. Mesh exposure describes a visible portion of mesh that has come through the vaginal wall but has not penetrated another organ. Mesh erosion describes mesh that has eroded into a neighbouring organ such as the bladder, urethra, or bowel. Mesh extrusion describes mesh that has migrated beyond its original site. The IUGA-ICS classification adopted in the IOG National Clinical Guideline (2023) provides the standard nomenclature. The distinction matters for both treatment route and litigation evidence: erosion into another organ is generally a more severe complication and supports stronger claims for general damages.

• Exposure: visible mesh in vaginal wall.
• Erosion: mesh into adjacent organ.
• Extrusion: mesh migrated beyond original site.

Why it matters: Precise diagnosis affects prognosis and damages.

Next step: IOG Clinical Guideline (2023)

What happens if HSE settles before trial?

Settlement of an HSE-defended mesh claim is managed by the State Claims Agency. Most settlements are made without admission of liability. The settlement figure is paid as a lump sum, with periodic payment orders available in catastrophic cases. Settlement closes the medical negligence and any consent claim against the State, but does NOT prevent a separate product liability claim against the device manufacturer if that route remains viable on the limitation analysis.

• State Claims Agency manages HSE settlements.
• No admission of liability is standard.
• Manufacturer claim may still proceed separately.

Why it matters: Multi-defendant claims need staged settlement strategy.

Next step: Compensation overview

Can I claim in the Republic if my mesh was placed in Northern Ireland?

Mesh implanted in a Northern Ireland hospital is governed by Northern Ireland law for the medical negligence claim. The product liability claim against an EU-established manufacturer can usually still be brought in the Republic of Ireland under EU jurisdiction rules where damage occurred here. Cross-border claims require co-ordinated handling because the underlying tests differ: NI follows the UK Bolam/Bolitho approach for clinical negligence and Montgomery for consent, while the Republic follows Dunne and Fitzpatrick.

• NI surgical claim governed by NI law.
• RoI manufacturer claim possible under EU rules.
• Hughes Report (UK) does not change either route.

Why it matters: Cross-border women often have routes in both jurisdictions.

Next step: Call 01 903 6408

What if I cannot remember exactly when my pain started?

Date of knowledge does not require a precise date. The statutory test under section 2 of the 1991 Amendment Act asks when you first knew (or reasonably should have known) that the injury was significant and was attributable to the act or omission alleged to be negligent. For mesh, the operative date is usually the date of confirmed diagnosis by a clinician, not the gradual emergence of symptoms. The clinical record will normally establish the date with sufficient precision. Section 71 concealment may further extend the period if a previous clinician dismissed the connection.

• Precise date not required.
• Confirmed diagnosis is usually the trigger.
• Section 71 concealment may extend.

Why it matters: Many women self-rule themselves out on date uncertainty wrongly.

Next step: Date of knowledge

What if my private health insurance paid for my original procedure?

Where private health insurance funded the implant or removal procedure, the insurer ordinarily has a subrogation right under the policy to recover its outlay from any damages award. Practically, the special damages claim includes the medical costs, and the settlement reflects them, with the insurer's subrogation managed by your solicitor. Your own out-of-pocket excess and uncovered costs are also recoverable. This rarely affects the underlying claim viability.

• Insurer subrogation handled within damages.
• Out-of-pocket costs separately recoverable.
• Does not reduce claim viability.

Why it matters: Some claimants worry about insurer interference. They should not.

Next step: Special damages guide

Follow-up scenarios: what if your facts are different

What if my hospital records say nothing about the consent discussion? Absent records on consent are themselves evidence of inadequate consent under Fitzpatrick. The burden of proving consent rests with the surgeon, and an empty record cannot discharge it.

What if my partner died from a mesh complication? The estate has standing under the Civil Liability Act 1961 to bring the claim on behalf of the deceased. A statutory dependants' action under section 48 may also be available for those financially or domestically dependent on the deceased.

What if the manufacturer has changed legal entity since my implant? Successor liability rules apply. The corporate restructuring does not extinguish the claim. Your solicitor will trace the producer chain through the Irish Companies Registration Office and EU registers.

What if multiple surgeons were involved in my mesh treatment? Each treating clinician is potentially a defendant in a multi-defendant proceeding. Apportionment of liability between them is a matter for the court at trial.

What if I had revision surgery already and the revision also failed? The revision itself can give rise to its own medical negligence claim with its own date-of-knowledge clock. The original implant claim is not displaced by a subsequent failure.

Glossary: mesh-specific terms used in this guide

TVT (tension-free vaginal tape)

The retropubic mid-urethral sling, the most common mesh used for stress urinary incontinence. Inserted via a small abdominal incision either side of the pubic bone.

TVT-O (tension-free vaginal tape obturator)

A variant of TVT inserted through the obturator foramen rather than retropubically. Designed to reduce the risk of bladder perforation but with different complication patterns.

TOT (transobturator tape)

An umbrella term for transobturator approaches to mid-urethral sling placement, including TVT-O.

Mid-urethral sling

The category of mesh used to support the urethra in stress urinary incontinence surgery. Includes TVT, TVT-O, and TOT variants.

Sacrocolpopexy

An abdominal procedure using mesh to suspend the vaginal vault to the sacrum. A different anatomical approach from transvaginal mesh and with a different complication profile.

Sacrospinous fixation

A native-tissue procedure (no mesh) suspending the vaginal vault from the sacrospinous ligament. Sometimes used as an alternative to mesh.

Mesh exposure

Mesh visible through the vaginal wall but not into another organ.

Mesh erosion

Mesh that has eroded into a neighbouring organ such as the bladder, urethra, or bowel.

Mesh extrusion

Mesh migration beyond its original anatomical site.

Dyspareunia

Pain during sexual intercourse. A frequent mesh complication and a recognised material risk under Fitzpatrick v White.

IUGA-ICS classification

The International Urogynecological Association and International Continence Society standard classification of mesh complications, adopted by the Irish Institute of Obstetricians and Gynaecologists in its 2023 National Clinical Guideline.

Partial excision

Surgical removal of the most problematic section of mesh, leaving the remainder in situ. More commonly performed in Ireland than complete excision.

Complete excision

Surgical removal of all mesh material. Technically demanding because mesh integrates with surrounding tissue. Often performed abroad.

Date of knowledge

The statutory date under section 2 of the Statute of Limitations (Amendment) Act 1991 when the plaintiff first knew or reasonably should have known the injury was significant and attributable to the act alleged to be negligent.

Longstop

A statutory cut-off after which a cause of action is extinguished regardless of date of knowledge. The 1991 Act longstop for product liability is ten years from the date the device was placed on the market.

State Claims Agency (SCA)

The State body that manages the defence of clinical negligence and certain product liability claims arising in HSE hospitals under the Clinical Indemnity Scheme.

Three-Route Mesh Claim Framework

Our framework for analysing Irish mesh claims as concurrent causes of action in medical negligence, product liability under the 1991 Act, and lack of informed consent under Fitzpatrick v White.

Date-of-Knowledge Reset

Our framework for cases where the limitation clock can be re-set under section 71 of the Statute of Limitations 1957 because a previous clinician dismissed the mesh as the cause and a later clinician confirmed it.

References and primary sources

All authorities cited above are listed here in formal citation format with primary-source URLs. ↑ Back to top

Legislation (Republic of Ireland)

1. Liability for Defective Products Act 1991 (Ireland). Available at: Irish Statute Book (irishstatutebook.ie).
2. Statute of Limitations (Amendment) Act 1991, section 2 (Ireland). Available at: Irish Statute Book.
3. Statute of Limitations 1957, section 71 (Ireland) (concealment). Available at: Irish Statute Book.
4. Personal Injuries Assessment Board Act 2003, section 3 (Ireland) (medical negligence exemption). Available at: Irish Statute Book.
5. Civil Liability and Courts Act 2004, section 8 (Ireland) (letter of claim). Available at: Irish Statute Book.
6. Legal Services Regulation Act 2015, section 150 (Ireland). Available at: Irish Statute Book.
7. Patient Safety (Notifiable Incidents and Open Disclosure) Act 2023 (Ireland) (commenced 26 September 2024). Available at: Irish Statute Book.

European Union legislation

8. Directive (EU) 2024/2853 of the European Parliament and of the Council of 23 October 2024 on liability for defective products. OJ L, 2024/2853, 18.11.2024. Transposition deadline: 9 December 2026. Available at: EUR-Lex (eur-lex.europa.eu).

Case law (Republic of Ireland)

9. Fitzpatrick v White [2007] IESC 51 (Supreme Court of Ireland, Kearns J, 15 November 2007). Available at: BAILII (bailii.org).
10. Geoghegan v Harris [2000] 3 IR 536 (High Court, Kearns J, 21 June 2000).
11. Dunne v National Maternity Hospital [1989] IR 91 (Supreme Court of Ireland, Finlay CJ).
12. Morrissey v HSE [2020] IESC 6 (Supreme Court of Ireland, Clarke CJ, 19 March 2020). Available at: BAILII.
13. Quinn v Mid-Western Health Board [2005] IESC 19 (Supreme Court of Ireland, Kearns J, 8 April 2005). Confirmed but-for as primary causation test. Rejected adoption of broader Fairchild-style alternatives.

Comparative authorities (England and Wales)

14. Bonnington Castings Ltd v Wardlaw [1956] AC 613 (House of Lords). Foundational English authority on material contribution to indivisible injury.

Practice Directions (High Court of Ireland)

15. President of the High Court, Practice Direction HC131: Clinical Negligence Actions - Applications for Trial Dates (effective 28 April 2025). Available at: Courts Service of Ireland.
16. President of the High Court, Practice Direction HC132: Clinical Negligence List (effective 28 April 2025). Available at: Courts Service of Ireland.

HSE, Department of Health, and clinical guidance

17. Health Service Executive, Pause on Vaginal Mesh Implants. Available at: hse.ie.
18. Health Service Executive, Vaginal mesh implants: overview. Available at: hse.ie.
19. Health Service Executive, Vaginal mesh implants: complications. Available at: hse.ie.
20. Health Service Executive, Support services for women with mesh complications. Available at: hse.ie.
21. Department of Health (Ireland), Office of the Chief Medical Officer, The Use of Uro-Gynaecological Mesh in Surgical Procedures (November 2018) (the Holohan Report, with 19 recommendations).
22. Institute of Obstetricians and Gynaecologists, National Clinical Guideline on the Diagnosis and Management of Mesh Complications (2023). Available at: rcpi.ie.

Regulatory authorities

23. Health Products Regulatory Authority, Reporting Safety Issues for Medical Devices. Available at: hpra.ie.
24. Health Products Regulatory Authority, Annual Report 2024 (3,672 medical device vigilance reports assessed in 2024).
25. Judicial Council of Ireland, Personal Injuries Guidelines (1st edition, adopted 6 March 2021). Available at: judicialcouncil.ie.
26. Injuries Resolution Board (formerly PIAB), Rules and Legislation. Available at: injuries.ie.

Oireachtas and parliamentary materials

27. Oireachtas Joint Committee on Health, hearing of 29 June 2022 (Mesh Survivors Ireland and Mesh Ireland addressed Committee, with combined membership of approximately 600 women).
28. Dáil Éireann, Hospital Procedures debate (1 May 2025): Department of Health confirmed it had recently received the National Vaginal Mesh Implant Oversight Group report.

Secondary commentary

29. Marian Fogarty, "Pelvic mesh scandal exposes regulatory gaps and data failures", Irish Legal News (April 2026). Available at: irishlegal.com.
30. Kate Ahern, "Untangling the threads", Law Society Gazette (November 2024). Analysis of the material contribution doctrine in Irish causation law.
31. Mason Hayes & Curran, "Calculating Damages for Multiple Injuries under the Personal Injuries Guidelines". Available at: mhc.ie.
32. William Fry, "The Future of Product Liability under the Revised EU Directive" (March 2025). Available at: williamfry.com.

Author: Gary Matthews, Principal Solicitor, Law Society of Ireland Practising Certificate No. S8178. Last reviewed: 6 May 2026. Sources verified: all primary-source URLs (Irish Statute Book, BAILII, Courts Service of Ireland, HSE, HPRA, EUR-Lex, Judicial Council) verified live as of 6 May 2026. Jurisdiction: Republic of Ireland.

Related guides: Medical negligence overview • Obstetrics & gynaecology negligence • Lack of informed consent • Surgical negligence • Date of knowledge • Expert medical reports • Compensation overview • No win no fee